How to optimize the study design 1. Theory and biological plausibility Paolo Vineis Firenze 19 June 2013.

Slides:



Advertisements
Similar presentations
Potential for Collaboration between EUCCONET and other European Projects Martine Vrijheid EUCCONET Workshop Feb, Paris.
Advertisements

Grant review at NIH for statistical methodology Jeremy M G Taylor Michelle Dunn Marie Davidian.
Asthma One child in 10 in the EU Childhood asthma costs the EU 3 Billion p.a. Adult and industrial asthma also 3 Billion Abnormal airway mucosa Intermittent.
Cancer Epidemiology Chapter 12 Mosby items and derived items © 2010, 2006 by Mosby, Inc., an affiliate of Elsevier Inc.
Cancer epidemiology Epidemiology & public health – understanding and control of disease at population level The scientific basis – knowledge through probability.
Dr Eva Batistatou. Outline of this presentation… What is epidemiology? The Fundamentals of Epidemiology course What is biostatistics? The Biostatistics.
Paolo Vineis Imperial College London Causal models of carcinogenesis: a historical perspective.
1 NEST New and emerging science and technology EUROPEAN COMMISSION - 6th Framework programme : Anticipating Scientific and Technological Needs.
Paolo Vineis University of Torino and ISI Foundation EPIC: Molecular markers of carcinogenesis in a large prospective study.
External validity: to what populations do our study results apply?
Assessment Report Biology School of Science and Mathematics Rey Sia, Chair Laurie B. Cook, Assessment Coordinator.
Deriving Biological Inferences From Epidemiologic Studies.
What is a sample? Epidemiology matters: a new introduction to methodological foundations Chapter 4.
Cancer Biology. 2 Outline 1.How do cancer cells differ from normal cells? Tumor progression Molecular basis for cancer.
Design Elements: Primitives. Try to Make these Primitives.
University of Turku Department of Biochemistry Jukka-Pekka Suomela Biomarkers.
Introduction of Cancer Molecular Epidemiology Zuo-Feng Zhang, MD, PhD University of California Los Angeles.
BIOST 536 Lecture 2 1 Lecture 2 - Modeling Need to find a model that relates the outcome to the covariates in a meaningful way  Simplification of the.
Introduction to Cancer Epidemiology
Introduction to Molecular Epidemiology Jan Dorman, PhD University of Pittsburgh School of Nursing
Biomedical research methods. What are biomedical research methods? An integrated approach using chemical, mathematical and computer simulations, in vitro.
Paolo Vineis Imperial College London and HuGeF Foundation Exposomics: a hybrid study design, and causal interpretation Centre Investigator’s seminar 26.
Georgia Wiesner, MD CREC June 20, GATACAATGCATCATATG TATCAGATGCAATATATC ATTGTATCATGTATCATG TATCATGTATCATGTATC ATGTATCATGTCTCCAGA TGCTATGGATCTTATGTA.
1 Epidemiology in Groningen What is epidemiology Our department Projects in our department Special Oncology.
Supercourse Environmental Exposure Assessment And Biomarkers Wael Al-Delaimy, MD, PhD.
BIOLOGIC MARKERS IN OCCUPATIONAL AND ENVIRONMENTAL MEDICINE By: Dr Chavoshi.
Zuo-Feng Zhang, MD, PhD Epi242, Prospective:  Cohort Studies: Observational studies  Intervention Studies, Clinical Trials  Nested Case-Control.
NCI’s Division of Cancer Epidemiology and Genetics
A brief introduction to Research Methodology By Dr.Shaikh Shaffi Ahamed Ph.d., Asst. Professor Dept. of Family & Community Medicine.
Lung Cancer Molecular Pathology of Cancer Boot Camp January 4, 2012 Jennifer Rider, ScD.
Non-Communicable Diseases
Chapter 15 Environmental Health, Pollution and Toxicology.
Introduction of Department of Molecular Biology for Public Health in SCDC Ye Lu Shanghai Municipal Center for Disease Control & Prevention Shanghai Institute.
©Edited by Mingrui Zhang, CS Department, Winona State University, 2008 Identifying Lung Cancer Risks.
Biomedical Research. What is Biomedical Research Biomedical research is the area of science devoted to the study of the processes of life; prevention.
Cancer: causes and treatment. Causes of mutations: Replication errors –Exacerbated by poor DNA repair Other biological agents –Viruses –Transposons Environmental.
Biobanks of Cerice Center for Gene Expression Research in Cancer Epidemiology Eiliv Lund, UiTø.
New Oslo PSC biobank.  Broad consent – covers all clinical and research biobanking  Integrated storage of clinical data and biological material  DNA,
THE CELL CYCLE AND CANCER. OK…what tells a cell when to divide (or, indeed, when NOT to divide)?
Lesson Overview Lesson Overview What Is Science? Lesson Overview 1.1 What Is Science?
ROLE OF GENE EXPRESSION:  Activation of a gene that results in a protein  Cells DO NOT need to produce proteins for every code. GENOME:  Complete genetic.
TOXICOGENOMICS.
Lesson Overview Lesson Overview What Is Science? Lesson Overview 1.1 What Is Science?
Dr Godfrey Grech University of Malta
WEDNESDAY, NOVEMBER 4, 2015 ABIDING FAITH CHRISTIAN CHURCH NUTRITION AND CANCER.
 Cancer: A disease that occurs through the growth of the abnormal cells, invasion and metastasis.  Unlike normal cells, cancer cells continue to grow.
Michael H. Dong MPH, DrPA, PhD  readings Epidemiology and Risk Assessment (4th of 10 Lectures on Toxicologic Epidemiology)
Organization of statistical research. The role of Biostatisticians Biostatisticians play essential roles in designing studies, analyzing data and.
Epidemiology 242: Cancer Epidemiology Zuo-Feng Zhang, MD, PhD Fall Quarter, 2009.
Lesson Overview Lesson Overview What Is Science? Lesson Overview 1.1 What Is Science?
D4FF55A0-6B6F BF422A9BA9 Present by: Xiao Chen On December 7, 2015.
What is Development? Systematic changes and continuities –In the individual –Between conception and death “Womb to Tomb” Three broad domains –Physical,
BIOSTATISTICS Lecture 2. The role of Biostatisticians Biostatisticians play essential roles in designing studies, analyzing data and creating methods.
Computational Biology and Genomics at Boston College Biology Gabor T. Marth Department of Biology, Boston College
Furan-Induced Cytotoxicity, Cell Proliferation, and Tumorgenicity in Mouse Liver Dr. Glenda Moser.
Headlines Introduction General concepts
An Introductory Lecture to Environmental Epidemiology Part 4. Some Issues in Exposure Assessment Mark S. Goldberg INRS-Institut Armand-Frappier, University.
Causes of Cancer By: Areana Eckman Valerie Hart Ashley Schuld Brandon Meade.
Prospects of genomics technologies in cancer molecular epidemiology Soterios A. Kyrtopoulos National Hellenic Research Foundation, Institute.
Biologic Monitoring A. H. Mehrparvar, MD
Action: BM0806 Recent Advances in Histamine Receptor H4R Research
Cancer Epidemiology Kara P. Wiseman, MPH, Phd
Biomedical Research.
How can we identify a novel carcinogen?
Review – First Exam Chapters 1 through 5
Potential for Collaboration between EUCCONET and other European Projects Martine Vrijheid EUCCONET Workshop Feb, Paris.
Using Mode of Action to Reduce Uncertainty in Risk Estimates
1.6 U.6 Mutagens, oncogenes and metastasis are involved in the development of primary and secondary tumours. Tumours are abnormal growth of tissue that.
Creating a good research question…
Generating reliable evidence on the determinants of NCDs
Presentation transcript:

How to optimize the study design 1. Theory and biological plausibility Paolo Vineis Firenze 19 June 2013

Scientific questions can be rather complex or sophisticated, and to assess causality you need “biological plausibility”, e.g. “is it plausible in terms of background biological knowledge that mobile phones cause cancer?” A way to address these issues is to incorporate biomarkers/omics into epidemiological studies

More sophisticated questions? Example

Armitage and Doll in 1954 proposed a multistage model based on the observation that the incidence rate of most epithelial tumors rises with a power of age (5-6th power). They hypothesized: - that cancer is not due to age itself but to prolonged duration of exposure to carcinogens - that for a life-long exposure an increase with a power of 6 means that there are 6 stages in carcinogenesis (6 mutations?) - for discontinued exposures the model becomes more complex Notice: all based on simple data on age distribution!

I(t)= r 1 r 2 … r (n-1) (t-w) n-1 where r is the transition rate from a stage to the following t is age w is the time mecessary to last-stage cells to give rise to a clinically overt cancer As an approximation: I(t)=K t n-1 (n-1) refers to the transition rates

The relationship with age holds true for most epithelial cancers (exponential of age: 6 for oesophagus, stomach, pancreas, bladder, rectum, colon), but not for lung and breast (cohort phenomena) THE BASIC IDEA IS THAT IT IS NOT AGE BUT DURATION OF EXPOSURE THAT COUNTS

EXPERIMENTS BY IVERSEN: TREATMENT OF MICE WITH DMBA (CARCINOGENESIS, 1991) A SINGLE DOSE OF 51.2 MICROGRAMS GAVE A TUMOR RATE OF 40%, WHILE THE SAME DOSE DIVIDED INTO 50 DOSES OF 1 MICROGRAM GAVE A 100% RATE Biological question: what is the role of mutations and what is the role of «promotion», cell proliferation, clonal expansion...?

Lessons (a) different mathematical models are compatible with the evidence on age-specific cancer incidence (b) different biological models (e.g. involving clonal expansion or stem cell death) are compatible with epidemiologic evidence (c) however, it is likely that selection of mutated clones AND of clones with mutator phenotype (explain) is involved (d) to answer these questions we need biomarkers!

Incorporation of biomarkers/omics into epidemiological research: design issues

Some environmental exposures can be studied by epidemiology with confidence, i.e. measurement error is relatively low and has little impact on estimates (e.g. smoking). Advancement in exposure assessment due e.g. to GIS techniques for air pollution. When measurement error is too high we need biomarkers (e.g. number of sexual partners, OR for cervical cancer around 2; HPV strains, OR around ).

Discoveries that support the original model of molecular epidemiology Marker linked to exposure or disease Exposure Internal dose Urinary metabolites (NNK, NNN) Nitrosocompounds in tobacco Biologically effective dose DNA adductsPAHs, aromatic compounds Albumin adducts AFB 1 Hemoglobin adducts Acrylamide, Styrene, 1,3-Butadiene Preclinical effect Exposure and/or cancer Chromosome aberrations Lung, Leukemia, Benzene HPRT PAHs, 1,3-Butadiene Glycophorin A PAHs Gene expression Cisplatin Genetic susceptibility Phenotypic markers DNA repair capacity in head and neck cancer SNPs NAT2, GSTM Bladder CYP1A1 Lung Vineis and Perera, 2007

The best design is the nested case-control study within a cohort Many population based cohorts exist in Europe, with related biobanks, both in adults and children Total size amounts to several millions people Largest include EPIC, UK Biobank Some are specialized (e.g. Sapaldia on air pollution), most are not

However... The measurement of most biomarkers with usual lab techniques requires large amounts of biological material E.g. PCB in serum 0.5 ml, 1 straw in EPIC Bulky DNA adducts 1-5 microg of DNA Need to explore the possibilities offered by new technologies, so called «omics»

“Individual and Population Exposomes” Cell (2008) 134:

Challenges in using cohorts: 1. precious biobanked material, not easily released by PIs 2. ethical issues 3. single (spot) biological samples 4. usually blood, not urine (which may be better e.g. for metabolomics) 5. no cohorts allow life-course epidemiology 6. in-depth exposure assessment is limited by feasibility (for cancer you need large sample sizes) 7. lab measurements and omics have the same limitations related to sample size and feasibility

“Creative study design”, i.e. when you are dealing with a very complex request (“mission impossible”) ENV Integrating environmental and health data to advance knowledge of the role of environment in human health and well-being in support of a European exposome initiative - FP7-ENV-2012-two- stage

The aim will be to exploit available or to-be-developed novel tools and methods (e.g. remote sensing/GIS-based/spatial analysis, 'omics'-based approaches, biomarkers of exposure, exposure devices and experimental models, new tools for combined exposures, novel study designs, burden of disease methodologies) to integrate and link environmental data with health data and information, and to apply them to (large-scale) population studies including new ones if deemed necessary (a concept that was recently proposed in the literature as 'exposome').

ALSPAC EPIC- ESCAPE PICCOLI+ Exposome: Totality of exposure from air, water, diet, lifestyle, behavior, metabolism, inflammation, oxidative processes, etc. - during all stages of life Critical stages of life - define Mid- and late-life Childhood Early Adulthood Adolescence Adulthood 60 Age Birth PISCINA INMA RHEA PISCINA RAPTES OXFORD ST MCC SAPALDIA EPICURO

EXPOsOMICs App -GPS position -Accelerometer (user activity) -Altimeter -Compass -user I/O (questionnaire) -Download of logged data (above) via USB -Application setup SmartPhone MicroAeth (BC) UFP Sensor USB hub USB Sensor Pack - “Dedicated” smart phone in a pouch on sensor pack to enable user input/output (i.e. we do not intend to “leverage” the user’s personal phone, at this stage). -Rechargable Li battery pack supplies power to instruments and smartphone via USB hub for 36 hr autonomy. -Each Sensor and Smartphone log data independently (synched in time during initial setup). USB Rechargeable Battery Pack (use 5V o/p.) PEM device

Blood Processing Protocol for Exposome Studies Peripheral Blood (45 ml) EDTA Tubes (10 ml x 2) Serum Tube (7 ml x 2) PAXgene (2.5 ml x 2) Centrifugation Plasma Buffy Coat RBC Ficoll PBMC Centrifugation SerumClot Adductomics, Bioassays, Chemicals DNA Sequencing -80 °C DNA -80 °C RNA mRNA & miRNA Arrays Protein G/RBC 1.5ml x 6 1.0ml x 67ml x 2 0.5ml x 2 0.2ml x °C Trace Element Tube (6 ml x 1) -80 °C Metals 0.5ml x 2 RNAProtector

Lessons on how to write a grant: - is exposure assessment good? - are you using validated laboratory tests? - are you collecting enough biological material? How will it be split into the labs? - is the design of the study able to use the MITM concept? - what about statistical power? - FEASIBILITY! - ethics